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While low levels of vitamin D can increase the risk for
osteoporosis, excessive amounts of vitamin D may also
be problematic. Hypercalcemia and hypercalcuria due
to increased vitamin D activity occur in a significant
proportion of sarcoidosis patients. Saidenberg-
Kermanac’h and colleagues compared vitamin D levels
with bone fragility fractures in their sarcoidosis clinic.
They found that a 25-(OH) vitamin D level between 10
and 20 ng/ml was associated with the lowest risk of
bone fractures and paradoxically higher levels increased
the risk of bone fractures. Using less vitamin D supple-
mentation may simultaneously lower the risk for bone
fracture and hypercalcemia in sarcoidosis.coids, sometimes for years. Obviously, long-term gluco-In the previous issue, Saidenberg-Kermanac’h and col-
leagues provide more information regarding the complexity
of vitamin D activity in sarcoidosis [1]. A few years ago,
vitamin D was declared the nutrient of the decade. This
was heady stuff for a sterol that was originally felt import-
ant only in preventing rickets. Studies have demonstrated
its key role in calcium absorption and bone growth. Beyond
that, vitamin D has been considered an important sterol in
various aspects of health. Low levels of vitamin D have
been associated with increased risk for cancer, type 2
diabetes, and heart disease.
Most of these observations have been based on measure-
ments of 25-(OH)-vitamin D3 (ergocalcitrol). This sterol is
converted by 1-alpha hydroxylase to 1,25-(OH)2-vitamin
D3 (calcitrol), the active form of vitamin D. This conversion
occurs in the kidney and patients with chronic renal failure
require calcitrol replacement.
In tuberculosis, vitamin D supplementation has been
recommended in patients because vitamin D is crucial in
the granulomatous reaction against the organism. However,* Correspondence: bob.baughman@uc.edu
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2014what may be good for tuberculosis eradication may not be
good for sarcoidosis. It has been noted that excessive
amounts of vitamin D are associated with a worse clinical
outcome in sarcoidosis [2]. In granulomas, there may be in-
creased activity of 1-alpha hydroxylase. As part of the Th-1
immune response, calcitrol has a paracrine effect within the
granuloma. In some cases, this leads to excessive calcitrol,
resulting in hypercalcuria or hypercalcemia [3]. At least 10%
of sarcoidosis patients have hypercalcemia, half of whom
can develop associated renal dysfunction [3,4]. In some
cases, hypercalcemic renal failure can be reversed by simply
withdrawing vitamin D supplementation [3]. There are case
reports of excessive vitamin D replacement leading to hyper-
calcemia in patients with mycobacterial infections [5].
The sarcoidosis patient may be treated with glucocorti-
corticoid administration places the patient at risk for
developing osteoporosis [6,7]. In rheumatoid arthritis,
patients undergoing prolonged glucocorticoid treatment
are recommended to receive calcium and vitamin D
replacement [8]. While this is the cornerstone of preven-
tion of osteoporosis, the role of calcium and vitamin D
replacement in sarcoidosis remains unclear [9].
Into this quandary comes the study by Saidenberg-
Kermanac’h and colleagues reported in the previous issue
of Arthritis Research & Therapy [1]. After studying a large
cohort of sarcoidosis patients from their clinic, the authors
found that fragility fractures occurred in nearly a quarter of
them. The fracture risk was increased for those treated with
corticosteroids. Although low levels of ergocalcitrol was an
independent risk for osteoporosis, ironically high levels of
ergocalcitrol were also associated with an increased risk for
osteoporosis. They found that ergocalcitrol levels of 10 to
20 ng/ml was associated with the lowest fracture risk for
patients. This J shaped risk for bone fragility has been noted
in non-sarcoidosis patients, although the proposed target
levels are higher for these patients [10]. For the clinician
treating sarcoidosis, one has to balance not only the risk for
osteoporosis, but also the risk for hypercalcemia and renal
failure (Figure 1).d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Schematic depicting vitamin D metabolism in the body from ergocalcitrol to calcitrol. The conversion is enhanced by increased
activity of 1-alpha hydroxylase activity in the granuloma of sarcoidosis patients. The untoward consequences of low or high vitamin D activity are
summarized at the bottom of the figure.
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http://arthritis-research.com/content/16/3/111One possible explanation for the lower ideal ergocalcitrol
level in sarcoidosis is the enhanced activity of 1-alpha
hydroxylase in sarcoidosis granulomas. The authors did not
provide information regarding calcitrol levels in their
patients. The proportion of calcitrol to ergocalcitrol appears
to be higher in sarcoidosis compared to non-sarcoidosis
conditions. In one study of 270 sarcoidosis patients, 80%
had low ergocalcitrol levels, but less than 1% had low
calcitrol levels. In fact, that study found that 10% of patients
had elevated calcitrol levels [3]. Those with elevated
calcitrol were more likely to have a history of hypercalcemia
or hypercalcuria. Higher levels of calcitrol have been
associated with more advanced pulmonary sarcoidosis [2].
The other potential benefits of vitamin D replacement in
sarcoidosis are unclear. Should sarcoidosis patients with
low ergocalcitrol but normal calcitrol levels be prescribed
vitamin D supplementation to reduce their risk for cancer
and type 2 diabetes? If so, do they increase their risk for
hypercalcemia or hypercalcuria? Could this increased vita-
min D intake raise the functional level of vitamin D even
higher and therefore increase the risk for osteoporosis?
To paraphrase Goldilocks, one does not want too little or
too much vitamin D. You want just the right amount.
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